Testing a new vaccine for the Chikungunya virus
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
This study is testing a new vaccine called HydroVax-CHIKV to see how safe it is and how well it helps your body fight off the Chikungunya virus, which can make people very sick, especially during outbreaks, and it's looking for volunteers to help find the best dose for protection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Najit Technologies, INC. NIH-funded |
| Lab location | 1 site (Beaverton, UNITED STATES) |
| Project ID | NIH-11009620 on NIH RePORTER |
What this research studies
This research investigates a new vaccine called HydroVax-CHIKV designed to protect against the Chikungunya virus, which can cause severe illness and has led to significant outbreaks globally. The study will involve a double-blind, randomized, placebo-controlled Phase 1 trial to assess the safety and immune response generated by the vaccine in participants. By using a peroxide-inactivated virus, the vaccine aims to provide a safe option for immunization, particularly for vulnerable populations. Participants will receive different doses to determine the most effective and safe level of vaccination.
Who could benefit from this research
Good fit: Ideal candidates for this research include healthy adults aged 21 and older who are interested in participating in vaccine trials.
Not a fit: Patients who are currently infected with Chikungunya virus or have severe underlying health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that protects against Chikungunya virus infections.
How similar studies have performed: While there has been significant interest in developing vaccines for Chikungunya, this specific approach using peroxide-inactivated virus is novel and has not been widely tested in clinical settings.
Where this research is happening
Beaverton, UNITED STATES
- Najit Technologies, INC. — Beaverton, United States (Active)
Researchers
- Principal investigator: Amanna, Ian James — Najit Technologies, INC.
- Study coordinator: Amanna, Ian James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.